Given that anti‐CXCL8 and anti‐CXCR1/2 drugs are in advanced stages of clinical development for the treatment of cancers and other diseases, combinatorial therapies involving these drugs and clinically available anti‐EGFR drugs are a real possibility.[29]. This evidence concerns the gene EGFR and cancer.